Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors by Kerry A. Whalen, Kavya Rakhra, Naveen K. Mehta, Alexander Steinle, Jennifer S. Michaelson, Patrick A. Baeuerle

Get full text

1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19 by Agapitos Patakas, Naveen K Mehta, Patrick A Baeuerle, Jennifer S Michaelson, Kristan A Meetze, Hannah M Findlay, Timothy B London

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression by Agapitos Patakas, Bochong Li, Naveen K Mehta, Kristan Meetze, Patrick A Baeuerle, Jennifer S Michaelson, Hannah M Findlay, Timothy B London

Get full text

1093 CLN-617 combines IL-2 and IL-12 in a single molecule to optimally balance safety and efficacy upon intratumoral injection by Naveen K Mehta, Patrick A Baeuerle, Jennifer S Michaelson, Laura Liu, K Dane Wittrup, Kristan A Meetze, Irina M Shapiro, Kavya Rakhra

1171 CLN-418, a clinical-stage B7H4 x 4–1BB bispecific antibody with potential to treat patients with a wide range of solid tumors by Yun He, Ella Ioffe, Bing Huang, Naveen K Mehta, Patrick A Baeuerle, Jennifer S Michaelson, Kristan A Meetze, Irina M Shapiro, Hanna Dobrowolska

771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients wit... by Evan Hall, Adi Diab, Sajeve Thomas, Randy Sweis, Anthony El-Khoueiry, Naveen K Mehta, Jennifer S Michaelson, Laura Liu, Reham Abdel-Wahab, Jeffrey A Jones, Kaida Wu, Benjamin S Maciejewski

194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial by Victor Moreno, Ignacio Melero, Michael Millward, Tracy Liu, Rafał Stec, Erika Hamilton, Ana Maria Arance, Jennifer S Michaelson, Laura Liu, Alexander I Spira, Judy S Wang, Irina M Shapiro, Kerry A Whalen, Jeffrey A Jones

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL by Melanie Märklin, Gundram Jung, Jonas S Heitmann, Joseph Kauer, Helmut R Salih, Stefanie Mueller, Bochong Li, Latifa Zekri, Naveen K Mehta, Martin Pfluegler, Kristan Meetze, Isabelle Sindel, Fabian Vogt, Lukas Osburg, Hans-Jörg Bühring, Sebastian Hörner, Patrick A Baeuerle, Jennifer S Michaelson

Get full text